Topical anti-cancer compositions and methods of use thereof -> Monitor Keywords
Fresh Patents
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations
site info Site News  |  monitor Monitor Keywords  |  monitor archive Monitor Archive  |  organizer Organizer  |  account info Account Info  |  
11/03/05 - USPTO Class 424 |  129 views | #20050244523 | Prev - Next | About this Page  424 rss/xml feed  monitor keywords

Topical anti-cancer compositions and methods of use thereof

USPTO Application #: 20050244523
Title: Topical anti-cancer compositions and methods of use thereof
Abstract: Described are skin-care compositions containing non denatured soy products and optionally other anti-cancer or anti-aging agents. The compositions can be applied topically to reduce the risk of UV-induced cutaneous tumors. (end of abstract)



Agent: Dann, Dorfman, Herrell & Skillman - Philadelphia, PA, US
Inventors: Miri Seiberg, Stanley S. Shapiro, Christine Paine, Allan H. Conney, Mou-Tuan Huang
USPTO Applicaton #: 20050244523 - Class: 424757000 (USPTO)

Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Plant Material Or Plant Extract Of Undetermined Constitution As Active Ingredient (e.g., Herbal Remedy, Herbal Extract, Powder, Oil, Etc.), Containing Or Obtained From Leguminosae (e.g., Legumes Such As Soybean, Kidney Bean, Pea, Lentil, Licorice, Etc.)

Topical anti-cancer compositions and methods of use thereof description/claims


The Patent Description & Claims data below is from USPTO Patent Application 20050244523, Topical anti-cancer compositions and methods of use thereof.

Brief Patent Description - Full Patent Description - Patent Application Claims
  monitor keywords



CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application is a continuation in part of U.S. Application Ser. No. 09/698,454 filed Oct. 27, 2000, the entire disclosure of which is incorporated by reference herein.

FIELD OF THE INVENTION

[0002] This invention relates to compositions containing non-denatured soy products, or soy trypsin inhibitors, and optionally additional anti-cancer or cosmetically active agents. These compositions can be applied topically to reduce the risk of UV-induced cutaneous tumors.

BACKGROUND OF THE INVENTION

[0003] Skin, the largest organ of the human body, is continuously exposed to environmental insults such as smoke, pollution, and ultraviolet (UV) irradiation. The thinning of the ozone layer, which is expected to progress for at least several decades, reduces a major barrier to the passage of ultraviolet-B radiation (UVB) through the atmosphere. UVB, that is., light whose wavelength is in the range between about 280 and about 320 nm, is the main cause of sunburn, tanning, aging of the skin, and skin cancer.

[0004] The non-melanoma skin cancers (NMSC), including basal-cell and squamous-cell carcinoma, are the most common types of cancer among Caucasian populations. The incidence of NMSC has increased worldwide over the last few decades. Increased recreational and occupational sunlight exposure is commonly regarded as one of the reasons for the higher incidence of cutaneous cancers. The increase in UVB exposure associated with the thinning of the ozone layer is another significant factor. Mortality from NMSC is low, but the estimated recurrence rate of about 50% after five years and the local invasiveness of this type of cancer result in high medical costs. Therefore, NMSC constitutes a substantial public health concern. (Reviewed in Holick and Kligman, editors: Biologic effects of light. Walter de Gruyter, Berlin and New York, 1992).

[0005] Photo-carcinogenesis results from a complex interplay of simultaneous and sequential biochemical events. These events, initiated by irradiation of an organism with UV light of an appropriate wavelength, include the formation of DNA photo-products, inaccuracies in DNA repair, mutation of proto-oncogenes and tumor suppressor genes, and UV-induced production of radical species which produce subsequent effects on existing mutations and independently induce further mutations. In addition, other epigenetic events such as immunological responses, antioxidant defenses, and dietary factors may influence the course of carcinogenesis. (Black, H. S., deGruijl, F. R., Forbes P. D., Cleaver, J. E., Ananthaswamy, H. N., deFabo, E. C., Ullrich, S. E., Tyrrell, R. M., Photo-carcinogenesis: an overview. J. Photochem. Photobiol. B 40:1, 29-47, August, 1997).

[0006] The skin possesses an elaborate antioxidant defense system to deal with UV-induced oxidative stress. Excessive exposure to UV radiation, however, can overwhelm the cutaneous antioxidant capacity, leading to oxidative damage and ultimately to skin cancer and premature skin aging. Therefore, one strategy for photo-protection is to support the endogenous antioxidant system by induction or transdermal delivery of antioxidant enzymes or nonenzymatic antioxidants. Antioxidants such as glutathione, alpha-tocopherol, ascorbate and beta-carotene have been found to be very effective in photoprotection. Components of the antioxidant pathway have also been identified and applied to the skin of patients. Although skin treatments with single components of the antioxidant system such as vitamin E were successful against a wide variety of types of photodamage, they were not shown to affect the progression of UV-induced tumors. The most promising results were obtained in studies combining several compounds, which often resulted in synergy between the protective effects. (Steenvoorden D. D., van Henegouwen G. M., The use of endogenous antioxidants to improve photoprotection, J. Photochem. Photobiol., B 41:1-2, 1-10, November, 1997).

[0007] Epidemiological studies suggest that components of vegetables, particularly legumes, are beneficial in lowering the incidence rates of many types of cancer. For example, the rates of breast, colon and prostate cancer are significantly lower among the inhabitants of most countries of the Pacific Basin, but offspring of Pacific Basin natives who have migrated to the United States develop the common Western cancers at approximately the same rate as native Westerners. Such epidemiological studies suggest that dietary and other environmental factors, rather than genetic differences, contribute more significantly to the risk of susceptibility to these cancers. The high consumption of soybean products in Pacific Basin countries, such as Japan, implicates diet as one factor contributing to the relatively extremely low rates of cancer mortality in these countries. (E.g., Wu et al., Soy intake and risk of breast cancer in Asians and Asian Americans. Am. J. Clin. Nutr. 68: 6 Suppl., 1437S-1443S, December, 1998).

[0008] Soybeans are a rich source of isoflavones, which possess weak estrogenic activity. Genistein, the main soybean isoflavone, is a specific inhibitor of protein tyrosine kinases and of other enzymes involved in signal transduction. Genistein has been shown to suppress the growth of numerous cancer cells in vitro, and to protect animals in experimental carcinogenesis models from developing both hormone- and non-hormone related cancers. (Reviewed in A. R. Kennedy, Chemopreventive agents: Protease inhibitors, Pharmacology Theories 78 (3), 167-209), 1998 and in Messina et al., Soy intake and cancer risks: A review of the in vitro and in vivo data, Nutrition and Cancer 21 (2), 113-131, 1994).

[0009] Soybeans also contain a number of protease inhibitors such as BBI and STI. It is important to note that soy foods do not contain high concentrations of active STI and BBI, because these protease inhibitors block the action of trypsin and other enzymes needed for protein digestion. Although STI is denatured by cooking, heat alone does not inactivate BBI, and consumption of soy products containing high levels of these protease inhibitors leads to serious digestive problems, chronic deficiency in amino acid uptake, and cancer. Indeed, the Chinese did not serve soybeans as food until fermentation techniques were developed to destroy the anti-digestive properties of the soy foods (2nd century B.C.E.). During the production of soy foods today, pureed soybeans are soaked in an alkaline solution and then pressure-heated to 115.sup.EC in order to denature the protease inhibitors as much as possible.

[0010] Limtrakul et al. attempted to identify a safe level of soy proteins for nutritional consumption, which would be beneficial in the prevention of cancer. Skin tumors were chemically induced in mice, which were fed soy protein isolate (SPI) exclusively, and in mice which were fed SPI supplemented with soymilk proteins (SMP). It was reported that "the percentage of tumor-bearing mice and the volume of tumor tended to be lower in the mice on the SMP diet". Life Sciences 1993, 53, 1591-1596. When defatted soybeans are treated first with alkaline, then with acid solution, SPI is the precipitate and SMP is the supernatant. The Limtrakul study shows the potential of soy proteins to affect skin cancer progression, when the proteins are orally consumed. However, it was also emphasized that higher levels of dietary intake of SMP would result in major health problems.

[0011] It is clear that a need exists for safe, efficacious and economical agents that prevent or reduce incidence of cancer, particularly for NMSC, which may be simply and conveniently administered. Further, economical and prophylactic compositions and methods for the reduction, prevention or inhibition of the progression of UV-induced cutaneous tumors are highly desirable. Since topical application is very simple and convenient, incorporating compositions that reduce skin cancer incidence into a skin-care product would be extremely advantageous. While sunscreens are known to reduce the damage resulting from UV exposure during the period of their application, there is a need for a skin care product that could also slow the progression of already-initiated photocarcinogenic processes. It is an object of the invention to provide such a product.

SUMMARY OF THE INVENTION

[0012] The present invention provides a method of reducing the risk of developing UV-induced tumors of the skin of a mammal by topically applying a skin-care composition, preferably to an individual who has already been exposed to or irradiated with UV light. A method of reducing the growth rate of UV-induced cutaneous tumors by topically applying the skin-care composition is also provided, as is a method of preventing the progression of cancer by the same means.

[0013] The skin care composition for use in the methods of the invention is formulated for the topical delivery of a non-denatured soy product (e.g., to a mammal such as a human) and comprises a soy product (e.g., a non-denatured soymilk or soybean powder or soybean trypsin inhibitor) and a vehicle. The composition may optionally comprise other anti-cancer or cosmetically active agents. Certain skin care compositions appropriate for use in the present invention have been described in U.S. patent application Ser. Nos.09/110,409, 09/621,565 and 09/698,454, filed Jul. 6, 1998, Jul. 21, 2000 and Oct. 27, 2000, respectively, and in International Application No. WO99/04752. Each of the foregoing patent documents is incorporated herein by reference.

[0014] Other features and advantages of the present invention will be apparent to those of skill in the art in light of the following description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIGS. 1A-1C are a series of graphs showing the inhibitory effects of STI and BBI on the development of skin tumors in SKH-1 mice previously treated with ultraviolet B light. (BSA--bovine serum albumin; BBI--Bowman-Birk Inhibitor; STI--Soy Bean Trypsin Inhibitor)

[0016] FIGS. 2A-2C are a series of graphs showing the inhibitory effect of Soymilk on the development of skin tumors in SKH-1 mice previously treated with ultraviolet B light. The inhibitory effects of heat-denatured soymilk vs. non-denatured soymilk are compared.

[0017] FIGS. 3A-3C are a series of graphs showing the inhibitory effects caffeine on the development of skin tumors in SKH-1 mice previously treated with ultraviolet B light.

[0018] FIGS. 4A-4C are three photographs showing the reduction in size and number of UV-induced tumors among mice treated topically with non-denatured soymilk (FIG. 4A) compared to mice treated with heat-denatured soymilk (FIG. 4B) or water (FIG. 4C).

[0019] FIGS. 5A and 5B are a pair of photographs showing the reduction in size and number of UV-induced tumors among mice treated topically with a solution of caffeine in acetone (FIG. 5B) compared to mice treated with acetone alone (FIG. 5A).

Continue reading about Topical anti-cancer compositions and methods of use thereof...
Full patent description for Topical anti-cancer compositions and methods of use thereof

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Topical anti-cancer compositions and methods of use thereof patent application.
###
monitor keywords

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Topical anti-cancer compositions and methods of use thereof or other areas of interest.
###


Previous Patent Application:
Blood sugar regulating product from soybean seeds
Next Patent Application:
Topical composition comprising feverfew
Industry Class:
Drug, bio-affecting and body treating compositions

###

FreshPatents.com Support
Thank you for viewing the Topical anti-cancer compositions and methods of use thereof patent info.
IP-related news and info


Results in 0.5058 seconds


Other interesting Feshpatents.com categories:
Qualcomm , Schering-Plough , Schlumberger , Seagate , Siemens , Texas Instruments , pbckp
filepatents (1K)

* Protect your Inventions
* US Patent Office filing
patentexpress PATENT INFO